Navigation Links
RiverVest Venture Partners(R), a St. Louis-Based Venture Capital Firm Focusing on Life Sciences, Closes on Fund II, Names John P. McKearn, Ph.D., Venture Partner
Date:4/11/2008

ST. LOUIS, April 11, 2008 /PRNewswire/ -- RiverVest Venture Partners announced today that it has completed fundraising for its second fund, RiverVest Venture Fund II, L.P., with total committed capital of $75 million from private investors. RiverVest's first fund, which was licensed as a Small Business Investment Company, had total private capital of $45 million, plus one tier of leverage from the Small Business Administration.

RiverVest co-founder and managing director Thomas C. Melzer said, "We are pleased by the significant increase in the amount of private capital committed to Fund II compared to Fund I, as well as the broadening of our institutional investor base that this increase reflects."

Out of 16 investments in RiverVest's Fund I, half were sourced in the Midwest, including three in St. Louis. "This strategy is appealing to institutional investors, who don't like narrow geographic limits but do like the attractive valuations available in the Midwest," said Jay W. Schmelter, also a RiverVest co-founder and managing director.

RiverVest's Fund I portfolio currently includes 10 active companies: Five in medical devices, three in biopharmaceuticals, one in specialty pharmaceuticals, and one in healthcare services. Eight of these are fully funded to profitability or an exit.

Fund II will pursue the same investment strategy as Fund I, with a focus on early-stage medical device and biopharmaceutical opportunities. The Fund II portfolio currently includes six active companies, three of which were co- founded by RiverVest.

"We invest nationally to diversify our portfolio and to build relationships with leading venture capital firms on the coasts - firms that will present investment opportunities to RiverVest as well as participate in those we originate," said Mr. Melzer. "At the same time, we are located in a region with many outstanding research institutions, but one that is under- served by the venture industry."

In addition to closing on Fund II, RiverVest Venture Partners announced that John P. McKearn, Ph.D., has joined the firm as Venture Partner.

Dr. McKearn brings 25 years of scientific and operational expertise in pharmaceutical research and development at Kalypsys, Inc., Pharmacia, G.D. Searle & Co., and E.I. DuPont de Nemours and Company.

"We've known John since Pfizer bought Pharmacia back in 2003 and have kept in close contact ever since," said Mr. Schmelter. "John's strong scientific training and operational expertise will further our capabilities in sourcing and adding value to our biopharmaceutical portfolio."

While leading Kalypsys, Inc., a privately held biotechnology company in San Diego, Dr. McKearn raised more than $150 million in private equity from 2003-2006. As head of Research for Searle and Pharmacia, Dr. McKearn was an important contributor to the discovery, development and launch of no fewer than eight new prescription drugs, including Celebrex, one of the leading pharmaceuticals to treat arthritis.

"I believe in the quality of RiverVest's personnel, investors and portfolio, along with their vast industry and academic networks," said Dr. McKearn. "Fund I has had an impressive track record, and I look forward to applying my expertise to building RiverVest's biopharmaceutical presence."

Dr. McKearn holds a Ph.D. in immunology from the University of Chicago and a B.S. in biology from Northern Illinois University. He currently serves as a member of the board of directors for IDM Pharma (formerly Epimmune) and for Keel Pharmaceuticals.

About RiverVest Venture Partners

RiverVest Venture Partners is a venture capital firm investing in promising life sciences companies nationwide. RiverVest applies both its capital and its team's diverse range of expertise to create and grow successful enterprises that address unmet medical needs in major markets. RiverVest's extensive national network and privileged access to opportunities throughout the Midwest enable the firm to build a diverse portfolio of innovative, product-focused companies. http://www.rivervest.com


'/>"/>
SOURCE RiverVest Venture Partners
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
2. Biopure Gives Update on Malaysia Joint Venture Discussions
3. Hank Plain Joins Morgenthaler Ventures as Partner
4. Dan Broderick Joins Prolog Ventures as Partner
5. DiObex Inc. to Present at BIO Mid-America Venture Forum
6. Siemens and Xintek Form Joint Venture to Develop Nanotechnology-Enabled Multi-Pixel X-ray Tubes
7. Altheus Therapeutics Secures $3.6 Million in Venture Capital
8. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
9. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
10. Elbit Medical Imaging Ltd. Announces that Plaza Centers Has Entered into a Joint Venture Partnership to Develop Residential and Office Projects in Romania
11. Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... 2017  Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... agreements with Nippon Shinyaku, Co., Ltd. for Defitelio ® ... daunorubicin liposome injection), or CPX-351, in Japan ... agreements, Nippon Shinyaku will receive exclusive rights to develop ... in return for an upfront payment to ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Crohn’s & Colitis ... inflammatory bowel diseases (IBD), and ReachMD , the nation’s largest medical education ... learners. , The partnership, which launched in the fall of 2016, includes ...
(Date:3/29/2017)... 29, 2017 "Surging application of gesture control ... government are expected to drive the growth of gesture ... recognition market is expected to be worth USD 18.98 ... between 2017 and 2022. The touchless sensing market is ... growing at a CAGR of 17.44% between 2017 and ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... Nerium International Mexico has been approved as an active member of the ... and protection among distributers and consumers in relationship marketing. This professional organization fosters ...
Breaking Biology Technology:
(Date:3/22/2017)... , March 21, 2017 Optimove ... used by retailers such as 1-800-Flowers and AdoreMe, ... — Product Recommendations and Replenishment. Using Optimove,s machine learning ... personalized product and replenishment recommendations to their customers ... on predictions of customer intent drawn from a ...
(Date:3/13/2017)... Future of security: Biometric Face Matching software  Continue ... ... to match face pictures against each other or against large databases. The recognition ... ... software for biometric Face Matching on the market. The speed is at 100 ...
(Date:3/6/2017)... MATEO, Calif. , March 6, 2017 /PRNewswire/ ... marketing and sales technology, today announced Predictive Sales ... solution for infusing actionable sales intelligence into Salesforce. ... to automatically enable their sales organizations with deep ... messages that allow for intelligent engagement. Predictive Sales ...
Breaking Biology News(10 mins):